Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French decree on cytogenetic testing:

This article was originally published in Clinica

Executive Summary

Prior authorisation from the government is needed for laboratories in France to perform cytogenetic testing antenatally or postnatally, including when they are being used as a means to determine the sex of a foetus or to determine whether an ultrasound follow-up is needed. That is the thrust of a decree published in the Journal officiel on November 30, which also sets out the levels at which these laboratories will be reimbursed for the tests. The decree also lays out the conditions under which reimbursement will be given.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel